FDA Advisory No. 2017-270 || Invitation to Present Submitted Petitions and Corresponding Evidences in connection with the Re-certification of Contraceptive Products

FDA Advisory No. 2017-270 

Invitation to Present Submitted Petitions and Corresponding Evidences in connection with the Re-certification of Contraceptive Products

On 21 August 2017, the Food and Drug Administration (FDA) issued Advisory No. 2017-253 to invite interested parties to submit their petitions and any corresponding evidence on the mechanism of action of the listed contraceptive products within ten (10) calendar days. At the end of the submission period, several parties expressed their interest to formally present their evidence in support of their petition/opposition/position.

In response to these requests, the FDA hereby opens the following dates for presentation of evidence to be held at Room 111, 1st Floor, FDA Main Building:
•    25 September 2017, Monday at 9:00 am to 12:00 pm
•    27 September 2017, Wednesday at 1:00 pm to 4:00 pm

Interested parties should register by sending an email to This email address is being protected from spambots. You need JavaScript enabled to view it. using the prescribed format below:

Subject:                      Presentation of Petitions and Evidence in connection with the Re-certification of Contraceptive Products

Name of Participant:     Name of Association/Marketing Authorization Holder [MAH], etc.
Category:                   Petitioner, or MAH, etc.
Name Attendees:        Please limit to five attendees per association/MAH
Contact No(s):            (+63) 917-123-45-67

A confirmation slip will be sent by email. The confirmation slip shall be presented at the reception on the day of the presentation of evidence. Only participants indicated on the list of confirmed attendees shall be accommodated. To assure all parties are given equal opportunity to present their evidence, each confirmed party is guaranteed one (1) hour to present them.

For information and guidance.

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter